Genome-wide association study of antipsychotic-induced QTc interval prolongation.
about
RING finger protein RNF207, a novel regulator of cardiac excitationEtiology of cardiovascular disease in patients with schizophrenia: current perspectivesThe epigenome, 4D nucleome and next-generation neuropsychiatric pharmacogenomicsNitric Oxide Synthase 1 Adaptor Protein, an Emerging New Genetic Marker for QT Prolongation and Sudden Cardiac DeathPharmacogenomics of adverse drug reactionsGenotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*DTime-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug EventsPharmacogenetics of antipsychotics.Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study.Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicinePharmacogenetics of Drug-Induced QT Interval Prolongation: An UpdateGenome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Relating human genetic variation to variation in drug responses.Pharmacogenetics of Potassium Channel Blockers.Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval.Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Genetic variation in the miR-708 gene and its binding targets in bipolar disorder.Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study.Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.Pharmacogenetics of second-generation antipsychotics.Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example.Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms.Epigenomic mapping and effect sizes of noncoding variants associated with psychotropic drug response.Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.Validation of a population-based method to assess drug-induced alterations in the QT interval: a self-controlled crossover study.Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples.Investigation of the SLC22A23 gene in laryngeal squamous cell carcinoma.
P2860
Q24305127-3FABA335-43DB-4961-97F6-F2DE2753CCA4Q26778485-B30E08CE-AADC-483F-B226-84A12BD7FC1CQ26785674-DE2370DE-3CB1-4A11-8200-10B7F2FEFC2BQ26859562-56786246-8E29-47DB-9D68-F84E12C48CD2Q27015820-017BA1A7-176A-44DC-A356-A482C3F9C604Q28486019-49E6854E-AE70-4E5B-9DEC-DB45E535CC38Q28554594-15EA52B3-EC85-4C23-9521-A3BAD4A001D0Q33836837-4E3BAE97-CF04-47F4-AB35-4FDEB4664B71Q34229109-0E642A7D-DE69-4C4E-9587-9AE491A9287BQ35135720-BE4EF494-2311-4041-BE62-88856841AACCQ35375788-694C1F80-78A2-4D51-9CF9-AEB0A39AB1C5Q36084069-962F8543-94BF-4441-8178-376253F2AAA1Q36135959-D61D727C-C26B-4005-B6D8-CB08BB8B8579Q36252524-016E8CC3-3F5A-42B0-905A-A5EAD695C40CQ36970927-A1F3FF92-CFD4-4B0C-820B-247683FAE4CBQ37154348-2FF79E09-DF88-42C8-AB11-43DC45183EBEQ37353278-A145F83A-DFB6-4282-838B-BDCFCA69156FQ37593741-53AB366B-84A1-42E1-A30F-88ACF3EA89B6Q37624739-5578558D-0C7D-45A6-A80A-CF5CEDC1A6C0Q38061501-079A8D9B-92D3-40ED-9793-3F72DE900F4DQ38133628-C078408D-6E05-4DF3-ACBF-0EF2E382AB4DQ38217628-F65FBE31-17B2-4A2D-A3E4-BAC2FEE3FEF2Q38630075-DF1575C7-4E84-4B3E-8938-AE2A4BA0E86DQ40418374-AFC05CAD-AD0D-4800-8A3A-7F00FFC06AF9Q40573761-91FEBF53-DB0C-4181-993D-434711BFAF82Q41869132-ECE2C98E-CFA3-4EB2-90C4-A3F64B7832D2Q44039631-8557D8D2-900A-4425-B273-373CEAC5E66FQ51300430-860C862A-762D-43A3-A8EA-A190AA94E73FQ55030406-138A2362-8C62-4339-A0ED-1542C2B005CD
P2860
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@ast
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@en
type
label
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@ast
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@en
prefLabel
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@ast
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@en
P2093
P2860
P356
P1476
Genome-wide association study of antipsychotic-induced QTc interval prolongation.
@en
P2093
D E Adkins
E J C G van den Oord
J A Lieberman
J L McClay
P F Sullivan
T S Stroup
P2860
P2888
P304
P356
10.1038/TPJ.2010.76
P577
2010-10-05T00:00:00Z
P5875
P6179
1045566201